Editing Cannabinoid (section)

==== Cannabidiol ====
{{Main|Cannabidiol}}
Cannabidiol (CBD) is mildly [[psychotropic]]. Evidence shows that the compound counteracts cognitive impairment associated with the use of cannabis.<ref name=2015CBDantipsychReview /> Cannabidiol has little affinity for [[Cannabinoid receptor#CB1|CB<sub>1</sub>]] and [[Cannabinoid receptor#CB2|CB<sub>2</sub>]] receptors but acts as an indirect antagonist of cannabinoid agonists.<ref name="recentadvances">{{cite journal | vauthors = Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO | title = Cannabidiol--recent advances | journal = Chemistry & Biodiversity | volume = 4 | issue = 8 | pages = 1678–1692 | date = August 2007 | pmid = 17712814 | doi = 10.1002/cbdv.200790147 | s2cid = 3689072 }}</ref> It was found to be an antagonist at the putative new cannabinoid receptor, [[GPR55]], a [[GPCR]] expressed in the [[caudate nucleus]] and [[putamen]].<ref>{{cite journal | vauthors = Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ | display-authors = 6 | title = The orphan receptor GPR55 is a novel cannabinoid receptor | journal = British Journal of Pharmacology | volume = 152 | issue = 7 | pages = 1092–1101 | date = December 2007 | pmid = 17876302 | pmc = 2095107 | doi = 10.1038/sj.bjp.0707460 }}</ref> Cannabidiol has also been shown to act as a [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] agonist.<ref name="pmid16258853">{{cite journal | vauthors = Russo EB, Burnett A, Hall B, Parker KK | title = Agonistic properties of cannabidiol at 5-HT1a receptors | journal = Neurochemical Research | volume = 30 | issue = 8 | pages = 1037–1043 | date = August 2005 | pmid = 16258853 | doi = 10.1007/s11064-005-6978-1 | s2cid = 207222631 }}</ref> CBD can interfere with the uptake of [[adenosine]], which plays an important role in biochemical processes, such as energy transfer. It may play a role in promoting sleep and suppressing arousal.<ref>{{cite journal | vauthors = Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS | title = Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 367 | issue = 1607 | pages = 3364–3378 | date = December 2012 | pmid = 23108553 | pmc = 3481531 | doi = 10.1098/rstb.2011.0389 }}</ref>

CBD shares a [[wikt:Precursor|precursor]] with THC and is the main cannabinoid in CBD-dominant ''Cannabis'' strains. CBD has been shown to play a role in preventing [[cannabis and memory|the short-term memory loss associated with THC]].<ref name=NatureCBDMemory>{{Cite journal| vauthors = Frood A |title=Key ingredient staves off marijuana memory loss |journal=Nature |doi=10.1038/news.2010.508|year=2010}}</ref>

There is tentative evidence that CBD has an anti-psychotic effect, but research in this area is limited.<ref>{{cite journal | vauthors = Leweke FM, Mueller JK, Lange B, Rohleder C | title = Therapeutic Potential of Cannabinoids in Psychosis | journal = Biological Psychiatry | volume = 79 | issue = 7 | pages = 604–612 | date = April 2016 | pmid = 26852073 | doi = 10.1016/j.biopsych.2015.11.018 | s2cid = 24160677 }}</ref><ref name="2015CBDantipsychReview">{{cite journal | vauthors = Iseger TA, Bossong MG | title = A systematic review of the antipsychotic properties of cannabidiol in humans | journal = Schizophrenia Research | volume = 162 | issue = 1–3 | pages = 153–161 | date = March 2015 | pmid = 25667194 | doi = 10.1016/j.schres.2015.01.033 | s2cid = 3745655 }}<!--|access-date=9 October 2015--></ref>